Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pulmonary Embolism | 89 | 2024 | 2376 | 13.780 |
Why?
|
Venous Thromboembolism | 57 | 2024 | 1671 | 10.250 |
Why?
|
Anticoagulants | 58 | 2024 | 4599 | 5.230 |
Why?
|
Venous Thrombosis | 25 | 2024 | 1239 | 5.120 |
Why?
|
Vena Cava Filters | 13 | 2023 | 252 | 4.860 |
Why?
|
Thrombosis | 20 | 2024 | 2968 | 4.600 |
Why?
|
Fibrinolytic Agents | 17 | 2023 | 2158 | 2.770 |
Why?
|
Enoxaparin | 4 | 2023 | 377 | 2.130 |
Why?
|
Registries | 38 | 2024 | 8089 | 1.820 |
Why?
|
Hemorrhage | 29 | 2023 | 3461 | 1.600 |
Why?
|
Heparin | 6 | 2023 | 1637 | 1.400 |
Why?
|
Thromboembolism | 5 | 2023 | 986 | 1.400 |
Why?
|
Acute Disease | 37 | 2023 | 7149 | 1.390 |
Why?
|
Atrial Fibrillation | 8 | 2024 | 5034 | 1.180 |
Why?
|
Sodium Potassium Chloride Symporter Inhibitors | 3 | 2018 | 135 | 1.120 |
Why?
|
Endocarditis | 3 | 2015 | 350 | 1.110 |
Why?
|
Hirudins | 4 | 2023 | 183 | 1.080 |
Why?
|
Hospitalization | 17 | 2022 | 10262 | 1.080 |
Why?
|
Cardiology | 6 | 2021 | 1668 | 1.040 |
Why?
|
Randomized Controlled Trials as Topic | 21 | 2024 | 9959 | 1.000 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 7 | 2024 | 3255 | 0.970 |
Why?
|
Postthrombotic Syndrome | 2 | 2022 | 28 | 0.960 |
Why?
|
Humans | 195 | 2024 | 744343 | 0.940 |
Why?
|
Vitamin K | 2 | 2024 | 295 | 0.930 |
Why?
|
Journal Impact Factor | 4 | 2020 | 156 | 0.840 |
Why?
|
Heart Diseases | 4 | 2020 | 2788 | 0.840 |
Why?
|
Thrombolytic Therapy | 8 | 2023 | 2161 | 0.820 |
Why?
|
Fibric Acids | 1 | 2021 | 25 | 0.820 |
Why?
|
Vaccination | 4 | 2023 | 3278 | 0.800 |
Why?
|
Vena Cava, Inferior | 4 | 2020 | 440 | 0.800 |
Why?
|
Iran | 7 | 2022 | 708 | 0.770 |
Why?
|
Saphenous Vein | 3 | 2013 | 532 | 0.770 |
Why?
|
Antiphospholipid Syndrome | 1 | 2022 | 173 | 0.760 |
Why?
|
P-Selectin | 1 | 2023 | 600 | 0.760 |
Why?
|
Niacin | 1 | 2021 | 116 | 0.760 |
Why?
|
Platelet Aggregation Inhibitors | 6 | 2022 | 3068 | 0.760 |
Why?
|
Glycosaminoglycans | 2 | 2020 | 624 | 0.750 |
Why?
|
Sinus Thrombosis, Intracranial | 1 | 2021 | 103 | 0.730 |
Why?
|
Coronavirus Infections | 5 | 2020 | 3133 | 0.730 |
Why?
|
Pneumonia, Viral | 5 | 2020 | 3240 | 0.720 |
Why?
|
Ventricular Dysfunction, Right | 3 | 2023 | 581 | 0.720 |
Why?
|
Peptide Fragments | 4 | 2023 | 5097 | 0.700 |
Why?
|
Troponin I | 1 | 2024 | 619 | 0.690 |
Why?
|
Oxygen Inhalation Therapy | 2 | 2022 | 367 | 0.670 |
Why?
|
Heart Failure | 10 | 2020 | 10900 | 0.660 |
Why?
|
Zinc | 2 | 2020 | 684 | 0.660 |
Why?
|
Risk Assessment | 30 | 2024 | 23338 | 0.650 |
Why?
|
Pandemics | 11 | 2023 | 8388 | 0.650 |
Why?
|
Recurrence | 19 | 2023 | 8340 | 0.640 |
Why?
|
Coronary Artery Bypass | 6 | 2021 | 2289 | 0.630 |
Why?
|
Periodicals as Topic | 4 | 2019 | 1432 | 0.630 |
Why?
|
Endpoint Determination | 2 | 2020 | 601 | 0.620 |
Why?
|
Cardiac Tamponade | 1 | 2019 | 173 | 0.610 |
Why?
|
Thrombophilia | 1 | 2020 | 305 | 0.610 |
Why?
|
Cardiovascular Diseases | 12 | 2021 | 15165 | 0.600 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2018 | 104 | 0.600 |
Why?
|
Risk Factors | 42 | 2024 | 72290 | 0.570 |
Why?
|
Pericardial Effusion | 1 | 2019 | 247 | 0.570 |
Why?
|
Ankle | 1 | 2019 | 327 | 0.560 |
Why?
|
Heart Atria | 2 | 2020 | 1357 | 0.540 |
Why?
|
Aged | 55 | 2024 | 163280 | 0.540 |
Why?
|
Foot | 1 | 2019 | 527 | 0.530 |
Why?
|
Administration, Oral | 5 | 2024 | 3913 | 0.530 |
Why?
|
Femoral Vein | 1 | 2016 | 159 | 0.520 |
Why?
|
Treatment Outcome | 32 | 2023 | 63114 | 0.490 |
Why?
|
Fee-for-Service Plans | 2 | 2018 | 694 | 0.490 |
Why?
|
Female | 74 | 2024 | 380194 | 0.470 |
Why?
|
Guideline Adherence | 7 | 2018 | 2266 | 0.460 |
Why?
|
Extracorporeal Membrane Oxygenation | 2 | 2021 | 1354 | 0.450 |
Why?
|
Lower Extremity | 4 | 2020 | 1158 | 0.450 |
Why?
|
Pyridones | 3 | 2023 | 712 | 0.440 |
Why?
|
Male | 66 | 2024 | 350118 | 0.440 |
Why?
|
Furosemide | 1 | 2013 | 167 | 0.430 |
Why?
|
Fatty Acids, Omega-3 | 1 | 2021 | 1344 | 0.410 |
Why?
|
Intensive Care Units | 6 | 2023 | 3679 | 0.410 |
Why?
|
Occupations | 1 | 2014 | 517 | 0.410 |
Why?
|
Medicare | 7 | 2023 | 6566 | 0.410 |
Why?
|
Stroke | 5 | 2023 | 9981 | 0.400 |
Why?
|
Education | 1 | 2014 | 543 | 0.390 |
Why?
|
Streptococcal Infections | 1 | 2015 | 638 | 0.390 |
Why?
|
Myocardial Infarction | 4 | 2023 | 11727 | 0.390 |
Why?
|
Plaque, Atherosclerotic | 2 | 2013 | 1519 | 0.390 |
Why?
|
Fluid Therapy | 1 | 2015 | 593 | 0.380 |
Why?
|
Congresses as Topic | 1 | 2015 | 764 | 0.370 |
Why?
|
Population Surveillance | 1 | 2021 | 2616 | 0.370 |
Why?
|
Heart Valve Diseases | 2 | 2015 | 1073 | 0.370 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 2 | 2022 | 3047 | 0.360 |
Why?
|
Neoplasms | 8 | 2023 | 21683 | 0.360 |
Why?
|
Hospital Mortality | 7 | 2021 | 5317 | 0.360 |
Why?
|
Antiviral Agents | 5 | 2023 | 2987 | 0.350 |
Why?
|
Aged, 80 and over | 28 | 2023 | 57776 | 0.350 |
Why?
|
Data Interpretation, Statistical | 1 | 2019 | 2716 | 0.350 |
Why?
|
Liver Cirrhosis | 1 | 2019 | 1863 | 0.340 |
Why?
|
Thrombocytopenia | 3 | 2022 | 1179 | 0.340 |
Why?
|
Middle Aged | 42 | 2023 | 213383 | 0.340 |
Why?
|
Patient Readmission | 7 | 2023 | 3114 | 0.340 |
Why?
|
National Health Programs | 1 | 2012 | 445 | 0.330 |
Why?
|
United States | 22 | 2023 | 69872 | 0.320 |
Why?
|
Prognosis | 20 | 2023 | 29063 | 0.320 |
Why?
|
Research Design | 3 | 2020 | 5987 | 0.320 |
Why?
|
Heparin, Low-Molecular-Weight | 2 | 2020 | 339 | 0.310 |
Why?
|
Databases, Factual | 9 | 2020 | 7729 | 0.310 |
Why?
|
Acute Coronary Syndrome | 4 | 2022 | 2337 | 0.310 |
Why?
|
Heart Valve Prosthesis Implantation | 2 | 2015 | 1536 | 0.300 |
Why?
|
Hemostasis | 2 | 2020 | 458 | 0.300 |
Why?
|
Spain | 6 | 2021 | 465 | 0.300 |
Why?
|
Recombinant Proteins | 4 | 2023 | 6622 | 0.300 |
Why?
|
Preventive Health Services | 1 | 2012 | 575 | 0.300 |
Why?
|
Prospective Studies | 24 | 2024 | 53288 | 0.290 |
Why?
|
Echocardiography | 2 | 2020 | 5102 | 0.290 |
Why?
|
Atherosclerosis | 2 | 2013 | 3445 | 0.280 |
Why?
|
Blood Coagulation | 1 | 2012 | 1127 | 0.280 |
Why?
|
Staphylococcal Infections | 1 | 2015 | 1400 | 0.280 |
Why?
|
Length of Stay | 5 | 2022 | 6309 | 0.260 |
Why?
|
Income | 1 | 2014 | 1913 | 0.260 |
Why?
|
Residence Characteristics | 2 | 2014 | 2050 | 0.260 |
Why?
|
Patient Care Management | 2 | 2018 | 306 | 0.250 |
Why?
|
Internal Medicine | 1 | 2011 | 1009 | 0.240 |
Why?
|
Cause of Death | 6 | 2021 | 3584 | 0.240 |
Why?
|
Clinical Trials as Topic | 2 | 2017 | 7913 | 0.240 |
Why?
|
Ultrasonography | 2 | 2020 | 5985 | 0.230 |
Why?
|
Lipoprotein(a) | 1 | 2008 | 435 | 0.230 |
Why?
|
Inflammation | 3 | 2020 | 10638 | 0.230 |
Why?
|
Purinergic P2Y Receptor Antagonists | 3 | 2022 | 361 | 0.230 |
Why?
|
Sulfonamides | 1 | 2013 | 1938 | 0.230 |
Why?
|
Reperfusion | 2 | 2023 | 284 | 0.230 |
Why?
|
Freedom | 1 | 2023 | 69 | 0.220 |
Why?
|
Postoperative Complications | 3 | 2020 | 15295 | 0.220 |
Why?
|
Vascular Diseases | 1 | 2011 | 1161 | 0.220 |
Why?
|
Europe | 3 | 2019 | 3339 | 0.220 |
Why?
|
Cohort Studies | 8 | 2024 | 40561 | 0.220 |
Why?
|
Catheters | 2 | 2023 | 425 | 0.220 |
Why?
|
Health Promotion | 2 | 2012 | 2205 | 0.220 |
Why?
|
Decision Support Techniques | 1 | 2012 | 1956 | 0.210 |
Why?
|
Drug Administration Schedule | 2 | 2021 | 4933 | 0.210 |
Why?
|
Sex Characteristics | 2 | 2023 | 2585 | 0.210 |
Why?
|
Lipid Regulating Agents | 1 | 2021 | 24 | 0.200 |
Why?
|
Risk | 4 | 2019 | 9687 | 0.200 |
Why?
|
Disease Management | 2 | 2013 | 2459 | 0.200 |
Why?
|
Bibliometrics | 2 | 2016 | 339 | 0.200 |
Why?
|
Patient Education as Topic | 1 | 2011 | 2278 | 0.200 |
Why?
|
Survival Rate | 8 | 2020 | 12788 | 0.190 |
Why?
|
Pyrazoles | 2 | 2021 | 1972 | 0.190 |
Why?
|
Esters | 1 | 2021 | 210 | 0.190 |
Why?
|
Coronary Artery Disease | 3 | 2021 | 6487 | 0.190 |
Why?
|
Anti-Inflammatory Agents | 2 | 2020 | 1790 | 0.190 |
Why?
|
Angiography | 3 | 2021 | 1639 | 0.190 |
Why?
|
Drug Administration Routes | 1 | 2020 | 153 | 0.180 |
Why?
|
Heart Rate | 2 | 2022 | 4091 | 0.180 |
Why?
|
Sulfhydryl Compounds | 1 | 2021 | 298 | 0.180 |
Why?
|
C-Reactive Protein | 1 | 2011 | 3778 | 0.180 |
Why?
|
Troponin | 2 | 2023 | 524 | 0.180 |
Why?
|
Embolism | 1 | 2023 | 408 | 0.180 |
Why?
|
Hallux Valgus | 1 | 2020 | 65 | 0.170 |
Why?
|
Public Health | 1 | 2012 | 2603 | 0.170 |
Why?
|
Patient Discharge | 3 | 2018 | 3313 | 0.170 |
Why?
|
Amides | 1 | 2021 | 459 | 0.160 |
Why?
|
Time Factors | 11 | 2022 | 40075 | 0.160 |
Why?
|
Sleep Apnea, Obstructive | 2 | 2022 | 1813 | 0.160 |
Why?
|
Syndrome | 2 | 2021 | 3251 | 0.160 |
Why?
|
Uncertainty | 1 | 2023 | 734 | 0.160 |
Why?
|
Smoke | 1 | 2019 | 227 | 0.160 |
Why?
|
Sex Factors | 4 | 2023 | 10397 | 0.160 |
Why?
|
Double-Blind Method | 2 | 2023 | 12026 | 0.150 |
Why?
|
Tissue Plasminogen Activator | 2 | 2021 | 1261 | 0.150 |
Why?
|
International Classification of Diseases | 1 | 2023 | 867 | 0.150 |
Why?
|
Healthcare Disparities | 4 | 2020 | 3158 | 0.150 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2021 | 10943 | 0.150 |
Why?
|
Practice Guidelines as Topic | 9 | 2018 | 7279 | 0.150 |
Why?
|
Graft Occlusion, Vascular | 2 | 2012 | 549 | 0.150 |
Why?
|
Research Report | 1 | 2020 | 355 | 0.150 |
Why?
|
Predictive Value of Tests | 6 | 2023 | 15076 | 0.150 |
Why?
|
Pericarditis | 1 | 2018 | 128 | 0.140 |
Why?
|
Protein Structure, Secondary | 1 | 2020 | 1246 | 0.140 |
Why?
|
Publishing | 2 | 2018 | 833 | 0.140 |
Why?
|
Algorithms | 5 | 2023 | 13881 | 0.140 |
Why?
|
Incidence | 9 | 2020 | 20947 | 0.140 |
Why?
|
Follow-Up Studies | 9 | 2020 | 39050 | 0.140 |
Why?
|
Adult | 18 | 2023 | 214055 | 0.140 |
Why?
|
Retrospective Studies | 16 | 2023 | 77449 | 0.140 |
Why?
|
Internationality | 2 | 2019 | 1003 | 0.140 |
Why?
|
Tachycardia | 1 | 2018 | 619 | 0.140 |
Why?
|
Confusion | 1 | 2018 | 275 | 0.130 |
Why?
|
Ischemia | 3 | 2021 | 1907 | 0.130 |
Why?
|
Drug Interactions | 1 | 2020 | 1460 | 0.130 |
Why?
|
Inpatients | 2 | 2022 | 2518 | 0.130 |
Why?
|
Multicenter Studies as Topic | 1 | 2020 | 1677 | 0.130 |
Why?
|
Organ Specificity | 1 | 2020 | 2008 | 0.130 |
Why?
|
Puerperal Disorders | 1 | 2018 | 275 | 0.130 |
Why?
|
Age Factors | 5 | 2023 | 18370 | 0.130 |
Why?
|
Veins | 1 | 2019 | 770 | 0.130 |
Why?
|
Health Care Costs | 3 | 2013 | 3209 | 0.130 |
Why?
|
Isotonic Solutions | 1 | 2015 | 119 | 0.130 |
Why?
|
Emergencies | 1 | 2021 | 1170 | 0.120 |
Why?
|
Severity of Illness Index | 5 | 2023 | 15540 | 0.120 |
Why?
|
Saline Solution, Hypertonic | 1 | 2015 | 110 | 0.120 |
Why?
|
Surgical Wound Dehiscence | 1 | 2015 | 215 | 0.120 |
Why?
|
Telecommunications | 1 | 2014 | 80 | 0.120 |
Why?
|
Withholding Treatment | 1 | 2018 | 599 | 0.120 |
Why?
|
Pharmaceutical Preparations | 1 | 2022 | 1071 | 0.120 |
Why?
|
Malnutrition | 1 | 2020 | 625 | 0.110 |
Why?
|
Aorta | 1 | 2021 | 2061 | 0.110 |
Why?
|
Pregnancy Complications, Cardiovascular | 1 | 2018 | 500 | 0.110 |
Why?
|
Blood Pressure | 3 | 2020 | 8554 | 0.110 |
Why?
|
Antihypertensive Agents | 2 | 2013 | 2046 | 0.110 |
Why?
|
Warfarin | 1 | 2021 | 1496 | 0.110 |
Why?
|
Kaplan-Meier Estimate | 2 | 2021 | 6538 | 0.110 |
Why?
|
Infusions, Intravenous | 2 | 2015 | 2274 | 0.110 |
Why?
|
Vaccines | 1 | 2021 | 822 | 0.110 |
Why?
|
Renal Replacement Therapy | 1 | 2015 | 257 | 0.110 |
Why?
|
Medical Informatics | 1 | 2019 | 745 | 0.110 |
Why?
|
Antithrombins | 1 | 2015 | 304 | 0.110 |
Why?
|
Stockings, Compression | 1 | 2012 | 37 | 0.100 |
Why?
|
Hypotension | 1 | 2018 | 884 | 0.100 |
Why?
|
Evidence-Based Medicine | 3 | 2012 | 3610 | 0.100 |
Why?
|
Cardiology Service, Hospital | 1 | 2014 | 246 | 0.100 |
Why?
|
Intracranial Hemorrhages | 1 | 2017 | 855 | 0.100 |
Why?
|
Canada | 2 | 2019 | 2065 | 0.100 |
Why?
|
Cost-Benefit Analysis | 3 | 2013 | 5391 | 0.100 |
Why?
|
Odds Ratio | 2 | 2021 | 9849 | 0.100 |
Why?
|
Middle East | 1 | 2012 | 219 | 0.100 |
Why?
|
Hemodynamics | 2 | 2018 | 4199 | 0.100 |
Why?
|
International Cooperation | 1 | 2018 | 1420 | 0.100 |
Why?
|
Diuretics | 1 | 2014 | 592 | 0.100 |
Why?
|
Anorexia Nervosa | 1 | 2020 | 1286 | 0.100 |
Why?
|
Pulmonary Artery | 1 | 2019 | 1912 | 0.100 |
Why?
|
Thoracoscopy | 1 | 2011 | 178 | 0.100 |
Why?
|
Immobilization | 1 | 2011 | 236 | 0.090 |
Why?
|
France | 1 | 2012 | 517 | 0.090 |
Why?
|
Surgery Department, Hospital | 1 | 2012 | 175 | 0.090 |
Why?
|
Transplants | 1 | 2012 | 209 | 0.090 |
Why?
|
Lung | 4 | 2022 | 9856 | 0.090 |
Why?
|
Myocardial Ischemia | 1 | 2021 | 2148 | 0.090 |
Why?
|
Leg | 2 | 2015 | 1116 | 0.090 |
Why?
|
Cross-Sectional Studies | 5 | 2020 | 25043 | 0.090 |
Why?
|
Africa | 1 | 2012 | 673 | 0.090 |
Why?
|
Orthopedic Procedures | 1 | 2020 | 1288 | 0.090 |
Why?
|
Mexico | 1 | 2012 | 690 | 0.090 |
Why?
|
Positive-Pressure Respiration | 1 | 2014 | 633 | 0.090 |
Why?
|
Medication Systems, Hospital | 1 | 2010 | 158 | 0.090 |
Why?
|
Germany | 1 | 2012 | 862 | 0.090 |
Why?
|
Intubation, Intratracheal | 2 | 2015 | 1364 | 0.090 |
Why?
|
Coronary Disease | 2 | 2018 | 6077 | 0.090 |
Why?
|
Quality of Health Care | 3 | 2015 | 4371 | 0.080 |
Why?
|
Acute Kidney Injury | 1 | 2022 | 1972 | 0.080 |
Why?
|
Obesity, Morbid | 1 | 2020 | 1213 | 0.080 |
Why?
|
United States Food and Drug Administration | 1 | 2017 | 1584 | 0.080 |
Why?
|
Forecasting | 1 | 2018 | 2951 | 0.080 |
Why?
|
Critical Care | 1 | 2021 | 2647 | 0.080 |
Why?
|
Sex Distribution | 1 | 2013 | 2297 | 0.080 |
Why?
|
Linear Models | 1 | 2018 | 5952 | 0.080 |
Why?
|
Heart Ventricles | 1 | 2020 | 3821 | 0.080 |
Why?
|
Hypolipidemic Agents | 1 | 2012 | 604 | 0.080 |
Why?
|
Critical Illness | 1 | 2020 | 2670 | 0.080 |
Why?
|
Brazil | 1 | 2012 | 1270 | 0.080 |
Why?
|
Age Distribution | 1 | 2013 | 2902 | 0.070 |
Why?
|
Heart | 1 | 2020 | 4467 | 0.070 |
Why?
|
Disease-Free Survival | 1 | 2018 | 6895 | 0.070 |
Why?
|
Reminder Systems | 1 | 2010 | 371 | 0.070 |
Why?
|
Reproducibility of Results | 2 | 2023 | 19905 | 0.070 |
Why?
|
Comorbidity | 4 | 2020 | 10388 | 0.070 |
Why?
|
Adolescent | 5 | 2023 | 85781 | 0.070 |
Why?
|
Sarcoma, Kaposi | 1 | 2009 | 370 | 0.070 |
Why?
|
Antibodies, Monoclonal | 1 | 2023 | 9274 | 0.070 |
Why?
|
Electronic Health Records | 1 | 2023 | 4468 | 0.070 |
Why?
|
Surgical Wound Infection | 1 | 2015 | 1540 | 0.070 |
Why?
|
Program Development | 1 | 2012 | 1316 | 0.070 |
Why?
|
Diagnostic Imaging | 1 | 2020 | 3507 | 0.070 |
Why?
|
Cardiovascular Agents | 1 | 2012 | 850 | 0.070 |
Why?
|
Health Resources | 1 | 2012 | 911 | 0.070 |
Why?
|
Aspirin | 2 | 2020 | 3282 | 0.070 |
Why?
|
Risk Reduction Behavior | 1 | 2012 | 1125 | 0.070 |
Why?
|
Pregnancy | 4 | 2021 | 29144 | 0.060 |
Why?
|
Physicians | 1 | 2023 | 4567 | 0.060 |
Why?
|
Medical Records | 1 | 2010 | 1413 | 0.060 |
Why?
|
Drug Costs | 1 | 2012 | 1105 | 0.060 |
Why?
|
Minority Groups | 1 | 2012 | 1223 | 0.060 |
Why?
|
Models, Statistical | 1 | 2019 | 5102 | 0.060 |
Why?
|
Mortality | 3 | 2023 | 2864 | 0.060 |
Why?
|
Early Detection of Cancer | 1 | 2018 | 3086 | 0.060 |
Why?
|
Propensity Score | 2 | 2021 | 1781 | 0.060 |
Why?
|
Longitudinal Studies | 1 | 2020 | 13989 | 0.060 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2021 | 9239 | 0.060 |
Why?
|
Stents | 1 | 2015 | 3280 | 0.060 |
Why?
|
Quality Improvement | 2 | 2018 | 3749 | 0.060 |
Why?
|
Reoperation | 1 | 2012 | 4201 | 0.050 |
Why?
|
Phenotype | 1 | 2020 | 16365 | 0.050 |
Why?
|
Quality Indicators, Health Care | 1 | 2013 | 1831 | 0.050 |
Why?
|
Glioblastoma | 1 | 2017 | 3481 | 0.050 |
Why?
|
Cytokines | 1 | 2017 | 7322 | 0.050 |
Why?
|
Ventilation-Perfusion Ratio | 1 | 2021 | 116 | 0.050 |
Why?
|
Animals | 4 | 2020 | 168757 | 0.050 |
Why?
|
Oxygen | 2 | 2023 | 4189 | 0.050 |
Why?
|
Hypertension, Pulmonary | 1 | 2012 | 1537 | 0.050 |
Why?
|
Weight Loss | 1 | 2012 | 2622 | 0.050 |
Why?
|
Fibrinolysis | 1 | 2021 | 322 | 0.050 |
Why?
|
Health Status Disparities | 1 | 2012 | 1797 | 0.050 |
Why?
|
Reference Values | 1 | 2008 | 4982 | 0.050 |
Why?
|
Lipids | 1 | 2011 | 3305 | 0.050 |
Why?
|
Hospitals | 1 | 2014 | 3952 | 0.050 |
Why?
|
Mental Disorders | 1 | 2020 | 6600 | 0.050 |
Why?
|
Smoking Cessation | 1 | 2012 | 2071 | 0.050 |
Why?
|
Patient Selection | 1 | 2012 | 4215 | 0.050 |
Why?
|
Survival Analysis | 1 | 2013 | 10252 | 0.040 |
Why?
|
Health Policy | 1 | 2012 | 2661 | 0.040 |
Why?
|
Case-Control Studies | 2 | 2020 | 21746 | 0.040 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2021 | 426 | 0.040 |
Why?
|
Phlebography | 1 | 2020 | 333 | 0.040 |
Why?
|
Syncope | 1 | 2022 | 429 | 0.040 |
Why?
|
Respiratory Care Units | 1 | 2018 | 10 | 0.040 |
Why?
|
Republic of Korea | 1 | 2020 | 539 | 0.040 |
Why?
|
Patient Advocacy | 1 | 2021 | 353 | 0.040 |
Why?
|
New York City | 1 | 2021 | 710 | 0.040 |
Why?
|
Perfusion Imaging | 1 | 2020 | 195 | 0.040 |
Why?
|
Thrombectomy | 1 | 2023 | 680 | 0.040 |
Why?
|
Smoking | 1 | 2015 | 8987 | 0.040 |
Why?
|
Data Collection | 2 | 2024 | 3341 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 4 | 2023 | 20129 | 0.040 |
Why?
|
Young Adult | 4 | 2020 | 56430 | 0.040 |
Why?
|
Radionuclide Imaging | 1 | 2021 | 2031 | 0.040 |
Why?
|
Systole | 1 | 2019 | 958 | 0.040 |
Why?
|
Tuberculosis | 1 | 2010 | 1912 | 0.040 |
Why?
|
Biomedical Research | 1 | 2013 | 3309 | 0.040 |
Why?
|
Logistic Models | 3 | 2021 | 13408 | 0.040 |
Why?
|
Perfusion | 1 | 2021 | 1360 | 0.040 |
Why?
|
Japan | 1 | 2021 | 1360 | 0.040 |
Why?
|
Cardiac Surgical Procedures | 1 | 2012 | 3537 | 0.040 |
Why?
|
Medication Errors | 1 | 2023 | 798 | 0.040 |
Why?
|
Myocardial Revascularization | 1 | 2021 | 841 | 0.040 |
Why?
|
Patients | 1 | 2023 | 900 | 0.040 |
Why?
|
Heart Transplantation | 1 | 2009 | 3110 | 0.030 |
Why?
|
Virus Internalization | 1 | 2020 | 501 | 0.030 |
Why?
|
Drug Utilization | 2 | 2014 | 1183 | 0.030 |
Why?
|
Ventricular Function, Right | 1 | 2020 | 591 | 0.030 |
Why?
|
Pain | 1 | 2011 | 4986 | 0.030 |
Why?
|
Systemic Inflammatory Response Syndrome | 1 | 2021 | 612 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2021 | 2971 | 0.030 |
Why?
|
Renin-Angiotensin System | 1 | 2020 | 759 | 0.030 |
Why?
|
Polysomnography | 1 | 2022 | 1776 | 0.030 |
Why?
|
Coronary Angiography | 2 | 2021 | 4577 | 0.030 |
Why?
|
Adaptive Immunity | 1 | 2020 | 713 | 0.030 |
Why?
|
Health Services Accessibility | 1 | 2012 | 5137 | 0.030 |
Why?
|
Health Services Research | 2 | 2013 | 1836 | 0.030 |
Why?
|
Sternum | 1 | 2015 | 177 | 0.030 |
Why?
|
Obesity | 1 | 2017 | 12745 | 0.030 |
Why?
|
Disease Progression | 2 | 2021 | 13284 | 0.030 |
Why?
|
Catheter Ablation | 1 | 2007 | 2758 | 0.030 |
Why?
|
Magnetic Resonance Angiography | 1 | 2020 | 1442 | 0.030 |
Why?
|
Statistics, Nonparametric | 1 | 2019 | 2886 | 0.030 |
Why?
|
Hypertension | 1 | 2013 | 8480 | 0.030 |
Why?
|
Hospital Bed Capacity | 1 | 2014 | 214 | 0.030 |
Why?
|
Triage | 1 | 2020 | 976 | 0.030 |
Why?
|
Prevalence | 2 | 2020 | 15226 | 0.030 |
Why?
|
Rural Population | 1 | 2023 | 2210 | 0.030 |
Why?
|
Dyspnea | 1 | 2020 | 1303 | 0.030 |
Why?
|
Myocarditis | 1 | 2020 | 771 | 0.030 |
Why?
|
Observer Variation | 1 | 2018 | 2593 | 0.030 |
Why?
|
Ambulatory Care | 1 | 2023 | 2708 | 0.030 |
Why?
|
Peer Review, Research | 1 | 2015 | 329 | 0.030 |
Why?
|
Access to Information | 1 | 2015 | 320 | 0.030 |
Why?
|
Aftercare | 1 | 2017 | 866 | 0.020 |
Why?
|
Rural Health Services | 1 | 2014 | 379 | 0.020 |
Why?
|
Skin Neoplasms | 1 | 2009 | 5686 | 0.020 |
Why?
|
Arrhythmias, Cardiac | 1 | 2020 | 2268 | 0.020 |
Why?
|
Pilot Projects | 1 | 2021 | 8324 | 0.020 |
Why?
|
Endothelium, Vascular | 1 | 2020 | 4456 | 0.020 |
Why?
|
Herpesvirus 8, Human | 1 | 2009 | 258 | 0.020 |
Why?
|
Health Status | 1 | 2020 | 4034 | 0.020 |
Why?
|
Neurosurgical Procedures | 1 | 2017 | 2002 | 0.020 |
Why?
|
Health Personnel | 1 | 2020 | 3218 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2021 | 13033 | 0.020 |
Why?
|
Lung Neoplasms | 1 | 2009 | 13102 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2018 | 3022 | 0.020 |
Why?
|
Wound Healing | 1 | 2015 | 2785 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2010 | 3508 | 0.010 |
Why?
|
Guidelines as Topic | 1 | 2007 | 1405 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2018 | 7659 | 0.010 |
Why?
|
Child | 1 | 2019 | 77709 | 0.010 |
Why?
|